Thinking and exploration on systemic treatment of hepatocellular carcinoma
10.3760/cma.j.cn115396-20240314-00075
- VernacularTitle:肝细胞癌系统性治疗的思考和探讨
- Author:
Yuling SUN
1
;
Rongtao ZHU
;
Weijie WANG
Author Information
1. 郑州大学第一附属医院肝胆胰外科 郑州大学肝胆胰疾病研究所，郑州 450052
- Keywords:
Carcinoma, hepatocellular;
Chemotherapy, adjuvant;
Antineoplastic protocols;
Systemic treatment;
Conversion therapy
- From:
International Journal of Surgery
2024;51(4):229-235
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma is the most common malignant tumor of the liver, and more than half of the patients are in the middle and late stage, seriously threatening the life and health of the Chinese people. Although surgical resection remains the only treatment option for liver cancer patients to achieve a cure, the low surgical resection rate and high postoperative recurrence rate greatly limit the survival benefits of patients. Recently, with the continuous successful development and clinical application of systemic new drugs, multi-mode therapy such as TKIs combined ICIs has sprung up, breaking the limitations of a single treatment model, and has become an important corner of "surgery-based comprehensive treatment" for liver cancer. Neoadjuvant therapy, adjuvant therapy and conversion therapy have gradually become the focus of new research, and their success is expected to further improve the survival prognosis of patients with liver cancer, but there are still many challenges. The author reviews the current first-line systematic treatment of liver cancer, and elaborates on the characteristics and advantages of its clinical application.
